<DOC>
	<DOCNO>NCT01329549</DOCNO>
	<brief_summary>This phase I , open label dose escalation study investigate addition BIBF 1120 treatment combination carboplatin Pegylated Liposomal Doxorubicin ( PLD ) patient advance , platinum sensitive relapse ovarian cancer , fallopian tube carcinoma primary peritoneal cancer . Patients treat BIBF 1120 together carboplatin PLD 6-9 repeat 28 day treatment course disease progression observe .</brief_summary>
	<brief_title>Dose Escalation Study BIBF 1120 Combination With Carboplatin PLD Relapsed Ovarian Cancer ( OC )</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion criterion : 1 . Female patient , age 20 year old , relapse histologically ( initial diagnosis ) confirm epithelial ovarian cancer , fallopian tube carcinoma primary peritoneal cancer 2 . Up 3 line prior chemo therapy , treatment free interval &gt; 6 month 3 . Platinum base chemotherapy immediately precede line . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance score 0 1 5 . Written inform consent consistent Good Clinical Practice ( GCP ) guideline Exclusion criterion : 1 . Prior chemotherapy PLD , contraindication therapy carboplatin PLD . 2 . More 2 line prior therapy contain angiogenesis inhibitor . 3 . Patients surgery plan , e.g . interval debulking surgery . 4 . History cerebral vascular accident , transient ischemic attack subarachnoid haemorrhage within past 6 month . 5 . Serious infection particular require systemic antibiotic ( antimicrobial , antifungal ) antiviral therapy . 6 . Laboratory value indicate increase risk adverse event . 7 . Significant cardiovascular disease .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>